Clinical data of patients with IGF-1Rabsent and IGF-1Rpresent MMCs and of patients with IL-6Rlow and IL-6Rhigh MMCs
Category . | IGF-1R, % of patients in each group . | IL-6R, % of patients in each group . | ||
---|---|---|---|---|
IGF-1Rabsent (n = 118), % . | IGF-1Rpresent (n = 53), % . | IL-6Rlow (n = 85), % . | IL-6Rhigh (n = 85), % . | |
Age ≥ 65 y | 26 | 21 | 26 | 24 |
Kappa light chain | 64 | 64 | 63 | 65 |
Lambda light chain | 33 | 34 | 36 | 32 |
Nonsecreting | 3 | 2 | 1 | 3 |
B2M ≤ 3.5 mg/mL | 60 | 58 | 63 | 56 |
B2M > 5.5 mg/mL | 17 | 17 | 19 | 15 |
IgA subtype | 20* | 33* | 15* | 33* |
LDH ≥ 240 IU/L | 26* | 12* | 24 | 19 |
Albumin < 35 g/L | 37 | 36 | 44 | 31 |
Hemoglobin < 10 g/dL | 31 | 32 | 29 | 34 |
C-reactive protein ≥ 5 mg/L | 40 | 40 | 43 | 38 |
Bone lesions | ||||
0, normal bone structure | 18 | 27 | 21 | 22 |
1, osteopenia/osteoporosis | 28 | 25 | 22 | 33 |
2, osteolyse (1–3) | 8 | 10 | 9 | 9 |
3, major structural damage (>3) | 46 | 38 | 48 | 36 |
Category . | IGF-1R, % of patients in each group . | IL-6R, % of patients in each group . | ||
---|---|---|---|---|
IGF-1Rabsent (n = 118), % . | IGF-1Rpresent (n = 53), % . | IL-6Rlow (n = 85), % . | IL-6Rhigh (n = 85), % . | |
Age ≥ 65 y | 26 | 21 | 26 | 24 |
Kappa light chain | 64 | 64 | 63 | 65 |
Lambda light chain | 33 | 34 | 36 | 32 |
Nonsecreting | 3 | 2 | 1 | 3 |
B2M ≤ 3.5 mg/mL | 60 | 58 | 63 | 56 |
B2M > 5.5 mg/mL | 17 | 17 | 19 | 15 |
IgA subtype | 20* | 33* | 15* | 33* |
LDH ≥ 240 IU/L | 26* | 12* | 24 | 19 |
Albumin < 35 g/L | 37 | 36 | 44 | 31 |
Hemoglobin < 10 g/dL | 31 | 32 | 29 | 34 |
C-reactive protein ≥ 5 mg/L | 40 | 40 | 43 | 38 |
Bone lesions | ||||
0, normal bone structure | 18 | 27 | 21 | 22 |
1, osteopenia/osteoporosis | 28 | 25 | 22 | 33 |
2, osteolyse (1–3) | 8 | 10 | 9 | 9 |
3, major structural damage (>3) | 46 | 38 | 48 | 36 |
The 171 previously untreated patients with MM were treated at the university hospitals of Heidelberg or Montpellier. Patients were separated into 2 groups: patients with IGF-1Rabsent MMCs and patients with IGF-1Rpresent MMCs or patients with IL-6Rlow MMCs and IL6Rhigh MMCs, as assayed with Affymetrix microarrays. Data are the percentages of patients within these 2 groups with the indicated clinical or biologic parameters.
B2M indicates β2-microglobulin; and LDH, lactate dehydrogenase.
The percentages were different with a χ2 test (P ≤ .05).